Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics (AVTX) management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 9, 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Avalo Therapeutics (AVTX) management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 9, 2026. The chat is scheduled for 8:30am ET. Management will also join a fireside chat at the Stifel 2026 Healthcare Conference on November 10, 2026 at 2:00pm ET. Webcasts and replays, when available, will be accessible through the company’s investor website, with archived replay available for at least 30 days.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/02/2026 - 04:00 PM EST

WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Guggenheim Healthcare Innovation Conference
Fireside Chat
November 9, 2026 at 8:30am ET

Stifel 2026 Healthcare Conference
Fireside Chat
November 10, 2026 at 2:00pm ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

For media and investor inquiries
Jonathan Neely
VP, Head of Investor Relations
jneely@avalotx.com

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com